Publications by authors named "Neal D Shore"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

20

Total Likes

259

Extended Reach

603,895

Social Features

114
U
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.
Edward D Esplin, Sarah M Nielsen, Sara L Bristow, Judy E Garber, Heather Hampel, Huma Q Rana, N Jewel Samadder, Neal D Shore, Robert L Nussbaum

JCO Precis Oncol· September 2022

Videos about Article: user

1 1 112 90

View All Article and Social Media Activity
A
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.
Georges Gebrael, Neeraj Agarwal, Alicia K Morgans, Randy Vince, Umang Swami, Neal D Shore

Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).
Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, Frederic Kinkead, Ibrahim Khilfeh, Neal D Shore

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, James L Bailen, Erik P M Roos

J Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial.
Neal D Shore, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka

J Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.
John L Gore, Erika M Wolff, Michael G Nash, Bryan A Comstock, Scott M Gilbert, Neal D Shore

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.
Soumyajit Roy, Yilun Sun, Maha Hussain, Kim N Chi, Karim Fizazi, Neal D Shore

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges.
Neal D Shore, Stephen J Freedland, Lisa G Horvath, Joe M O'Sullivan, Ugo De Giorgi

Eur Urol Focus· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.
Nicole Handa, Neal D Shore, Matthew R Cooperberg, Elai Davicioni, Xin Zhao

BJU Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, Michał Krawczyński, Artur Seyitkuliev, Neal D Shore

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Alicia K Morgans, Alex Chehrazi-Raffle, Tamim Niazi, Neal D Shore, Ashley E Ross

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Neal D Shore

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.
Neal D Shore, Ugo De Giorgi, Matko Kalac, Yiyun Tang, Ruslan Croitoru

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.
Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Neal D Shore

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
Neal D Shore, K Kent Chevli, Daniel Saltzstein, Yaron Ehrlich, Jay D Raman

Clin Genitourin Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T Gotto

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis.
Stephen J Freedland, Ugo De Giorgi, Antti Rannikko, Fred Saad, Miguel Ramirez-Backhaus, Neal D Shore

EClinicalMedicine· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.
Neal D Shore, Christopher M Pieczonka, Sean Heron, Mukaram Gazi, David J Cahn

Prostate Cancer Prostatic Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.
Taeweon Lee, Ayushi Gianchandani, Stephen A Boorjian, Neal D Shore, Vikram M Narayan

Future Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, André P Fay, Neal D Shore

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, André P Fay, Nobuaki Matsubara, Neal D Shore

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Podcast on Integrating Genetic Testing for Homologous Recombination Repair Gene Alterations in Patients with Prostate Cancer in the USA: a Multidisciplinary Approach to Overcoming the Obstacles.
Brittany M Szymaniak, Alicia K Morgans, Neal D Shore

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.
Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, Jose A Arranz, Philippe Barthélémy, Neal D Shore

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review.
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, Arun A Azad, Ciara Conduit, Neal D Shore

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis